Electromed, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2012, with comparison to fiscal 2011. The supplied metadata references “2011 Q4,” but the filing is an annual report for fiscal 2012, not a quarterly filing.
Business Context
Electromed develops, manufactures and sells SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation technology. Products are sold into home-care, institutional and international markets and generally require physician prescription and third-party reimbursement. International sales represented approximately 2.8% of fiscal 2012 revenue, down from 3.2% in fiscal 2011.
Robert D. Hansen retired as Chairman and Chief Executive Officer in May 2012. Chief Operating Officer James J. Cassidy became Interim Chief Executive Officer. The Company had 91 employees, including 86 full-time employees, as of June 30, 2012.
Financial Performance and Metrics
| Metric | Fiscal 2012 | Fiscal 2011 | Change |
|---|---|---|---|
| Net revenue | $19.524 million | $19.004 million | 2.7% increase |
| Gross profit | $14.145 million | $13.778 million | 2.7% increase |
| Gross margin | 72.4% | 72.5% | Down 0.1 percentage point |
| Operating income | $606,000 | $1.870 million | Decrease of $1.264 million |
| Net income | $187,000 | $1.056 million | Decrease of $869,000 |
| Net margin | 1.0% | 5.6% | Down 4.6 percentage points |
| Diluted EPS | $0.02 | $0.13 | Decrease |
| Research and development expense | $921,000 | $1.034 million | Decrease of $113,000 |
Home-care revenue increased 3.5% to $17.959 million. International revenue declined 10.0% to $547,000, while government and institutional revenue declined 2.9% to $1.018 million.
SG&A expense increased 16% to $12.618 million. Key increases included payroll and compensation, additional management and sales personnel, public-company compliance costs, sales-force turnover and approximately $482,000 of severance and other costs related to the retirement of two former officers. Interest expense declined to $169,000 from $191,000, while income tax expense declined to $251,000 from $623,000. The effective tax rate increased to approximately 57.0% from 37.1%.
Cash Flow, Liquidity and Debt
- Cash and cash equivalents declined to $1.702 million at June 30, 2012 from $4.092 million at June 30, 2011.
- Operating activities used $1.172 million of cash, compared with $1.415 million used in fiscal 2011. Working-capital uses included increases of $1.258 million in accounts receivable and $536,000 in inventories.
- Investing activities used $849,000, principally for $792,000 of property and equipment expenditures and $62,000 of patent and trademark costs.
- Financing activities used $369,000, including approximately $409,000 of principal payments on debt, partly offset by option exercises and subscription-note collections.
- The Company had $1.768 million outstanding on its revolving credit line and $1.588 million of term-loan debt, for total U.S. Bank facility borrowings of approximately $3.356 million.
- Net unused availability under the revolving line was approximately $3.116 million. The line bears interest at LIBOR plus 3.08% and expires December 31, 2013, if not renewed.
- Long-term debt, including current maturities, totaled approximately $1.644 million at June 30, 2012. Term Loan B, with approximately $176,000 outstanding, was due in December 2012.
Management stated that cash, cash equivalents and available borrowings were expected to provide adequate liquidity for the following year, but noted that additional financing might be required if operating performance or capital needs differed from expectations.
Material Changes and Unusual Items
- Revenue growth slowed materially from 32.9% in fiscal 2011 to 2.7% in fiscal 2012, primarily because of domestic sales-force turnover and downward reimbursement pressure.
- Profitability declined sharply because expenses for recruitment, staffing additions and management expansion did not produce the anticipated sales growth.
- The Company experienced a fixed-charge coverage covenant violation as of June 30, 2012. U.S. Bank waived the resulting event of default in a September 21, 2012 amendment, which also modified the covenant to exclude certain one-time retirement expenses and tax overpayments.
- The retirement of the former CEO created obligations including $209,000 of salary payable December 1, 2012, approximately $96,000 of earned bonus paid in July 2012 and estimated COBRA payments of $16,500.
- Estimated unrecognized installment-method sales increased to $1.901 million from $1.132 million. Revenue recognized under installment sales declined to $841,000 from $936,000.
- The warranty reserve increased to $610,000 from $444,000.
- The Company reported no material litigation expected to adversely affect financial condition or results. A prior SmartVest trademark dispute with Hill-Rom was settled in 2010 without material impact.
- The Company had no off-balance-sheet arrangements. The independent auditor issued an unqualified opinion on the consolidated financial statements; auditor attestation of internal controls was not required because Electromed was a smaller reporting company.
Outlook, Risks and Management Commentary
Management expected future growth from aggressive sales and marketing, improved customer value, product-line opportunities and international distributor expansion. The Company intended to spend approximately 5% of revenue on research and development for the foreseeable future.
- Revenue depends significantly on Medicare, Medicaid and private-insurance reimbursement, which may be reduced, restricted or delayed.
- Accounts receivable and revenue estimates are exposed to changes in insurance coverage, patient eligibility, payment delays and installment collections.
- The business faces competition from other HFCWO systems and alternative airway-clearance therapies.
- Medical-device operations require continuing FDA, international regulatory and quality-system compliance; failures could result in recalls, restrictions, penalties or loss of clearances.
- Sales-force turnover, reimbursement changes, international economic conditions and health-care cost-containment initiatives could constrain growth.
- The credit facility contains financial and operational covenants restricting dividends, additional debt, investments, changes in executive leadership and certain corporate transactions.
- The Company had related-party transactions with a research-and-development provider and a parts supplier affiliated with directors or former executives.
Investor Verification Checklist
- Verify current reimbursement rates, payer coverage criteria and collection performance for SmartVest systems.
- Review subsequent filings for repayment or refinancing of Term Loan B and continued compliance with U.S. Bank covenants.
- Assess whether the rebuilt sales organization converted into stronger revenue growth and improved operating leverage.
- Reconcile accounts receivable, installment-method sales and cash collections, particularly given the $1.901 million of unrecognized installment sales.
- Review the financial impact of executive departures, severance obligations and the transition to permanent leadership.
- Monitor warranty claims, product liability exposure, FDA compliance and the company’s patent portfolio, including patents approaching expiration.
- Evaluate related-party arrangements and confirm whether the discontinued research-and-development agreement affected future product development capacity.